Kymera Therapeutics Inc’s filing revealed that its Director Esposito Pamela unloaded Company’s shares for reported $2.26 million on Dec 17 ’25. In the deal valued at $82.16 per share,27,563 shares were sold. As a result of this transaction, Esposito Pamela now holds 0 shares worth roughly $0.0.
Then, PAMELA ESPOSITO bought 27,563 shares, generating $2,320,529 in total proceeds.
Before that, Booth Bruce sold 229,809 shares. Kymera Therapeutics Inc shares valued at $21,080,724 were divested by the Director at a price of $91.73 per share. As a result of the transaction, Booth Bruce now holds 686,477 shares, worth roughly $57.66 million.
A number of analysts have revised their coverage, including B. Riley Securities’s analysts, who remained covering the stock and in late October has reiterated a ‘”a Buy”‘ rating for it. Mizuho began covering KYMR with “an Outperform” recommendation on October 21, 2025. H.C. Wainwright maintained its rating on September 18, 2025. It rated KYMR as “a Buy”.
Price Performance Review of KYMR
On Friday, Kymera Therapeutics Inc [NASDAQ:KYMR] saw its stock jump 5.48% to $83.99. Over the last five days, the stock has lost -6.34%. Kymera Therapeutics Inc shares have risen nearly 98.56% since the year began. Nevertheless, the stocks have risen 108.77% over the past one year. While a 52-week high of $103.00 was reached on 12/08/25, a 52-week low of $19.44 was recorded on 04/09/25.
Levels Of Support And Resistance For KYMR Stock
The 24-hour chart illustrates a support level at 81.91, which if violated will result in even more drops to 79.84. On the upside, there is a resistance level at 85.35. A further resistance level may holdings at 86.72.
How much short interest is there in Kymera Therapeutics Inc?
A steep rise in short interest was recorded in Kymera Therapeutics Inc stocks on 2025-11-28, growing by 0.64 million shares to a total of 8.69 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-31 was 8.05 million shares. There was a rise of 7.38%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on September 17, 2025 when Barclays began covering the stock and recommended ‘”an Overweight”‘ rating along with a $60 price target.
